Component trials of USCP
| Trial | Number of patients | Carvedilol: placebo | NYHA II/III (%) | Primary end point |
| Mild CHF | 366 | 2:1 | 85/15 | Progression of CHF |
| MOCHA | 345 | 3:1 | 46/52 | Exercise tolerance (DRS) |
| PRECISE | 278 | 1:1 | 40/57 | Exercise tolerance |
| Severe CHF | 105 | 2:1 | 0.5/86 | QoL |
DRS, dose response study; QoL, quality of life